- Home
- / Taiwan Liposome
Taiwan Liposome
Revenue
NT$101.9 M
FY, 2020
Taiwan Liposome Summary
Company Summary
- Overview
- Taiwan Liposome operates as a biopharmaceutical company. It provides drug delivery technology development, new drugs researches, and other services. The Company also produces lipid based formulations, parenteral drugs, and other products.
- Type
- Private
- Status
- Active
- Founded
- 1997
- HQ
- Taipei, TW | view all locations
- Cybersecurity rating
Table of Contents
Key People
George Yeh, President
Tanvex Biopharma, Director
Wayne Liao, Director of Operations
LocationsView all
4 locations detected
Taipei HQ
Taiwan
2F, 3 Yuanqu Street, Nangang District
South San Francisco, CA
United States
Building 83, 611 Gateway Blvd #830
港区, 東京都
Japan
4/F
Leiden, ZH
Netherlands
Biopartner Gebouw 2, J.H. Oortweg 19
Taiwan Liposome Financials
Summary Financials
- Revenue (Q2, 2021)
- NT$160.2M
- Gross profit (Q2, 2021)
- NT$172.1M
- Net income (Q2, 2021)
- (NT$75.5M)
- Cash (Q2, 2021)
- NT$696.7M
- EBIT (Q2, 2021)
- (NT$79.3M)